S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
Sell every Stock except ONE (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
What’s At Stake In April is Shocking (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NASDAQ:ACAD

ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News

$18.82
+0.12 (+0.64%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$18.65
$19.10
50-Day Range
$18.24
$20.92
52-Week Range
$12.24
$28.06
Volume
878,701 shs
Average Volume
1.56 million shs
Market Capitalization
$3.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.44

ACADIA Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.41 Rating Score
Upside/​Downside
13.9% Upside
$21.44 Price Target
Short Interest
Bearish
5.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.28mentions of ACADIA Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$427,672 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.56) to ($0.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

487th out of 1,004 stocks

Pharmaceutical Preparations Industry

226th out of 489 stocks


ACAD stock logo

About ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Stock News Headlines

Satsuma Pharmaceuticals (STSA) Gets a Hold from Mizuho Securities
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Amylyx Pharmaceuticals Inc (AMLX) Gets a Buy from Citigroup
Stocks are for suckers – try this instead
This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...
Psychedelic Medicine Market Analysis, Share by 2028
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
See More Headlines
Receive ACAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACAD Company Calendar

Last Earnings
2/27/2023
Today
3/31/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACAD
Employees
514
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.44
High Stock Price Forecast
$33.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+13.9%
Consensus Rating
Hold
Rating Score (0-4)
2.41
Research Coverage
17 Analysts

Profitability

Net Income
$-215,980,000.00
Pretax Margin
-41.27%

Debt

Sales & Book Value

Annual Sales
$517.23 million
Book Value
$2.47 per share

Miscellaneous

Free Float
116,157,000
Market Cap
$3.05 billion
Optionable
Optionable
Beta
0.59

Key Executives

  • Stephen R. DavisStephen R. Davis
    Chief Executive Officer & Director
  • Brendan P. TeehanBrendan P. Teehan
    Chief Operating Officer, EVP & Head-Commercial
  • Mark C. Schneyer
    Chief Financial Officer & Executive Vice President
  • Ponni Subbiah
    Chief Medical Officer & Senior Vice President
  • Sanjeev Pathak
    Senior Vice President & Head-Clinical Development













ACAD Stock - Frequently Asked Questions

Should I buy or sell ACADIA Pharmaceuticals stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View ACAD analyst ratings
or view top-rated stocks.

What is ACADIA Pharmaceuticals' stock price forecast for 2023?

17 analysts have issued twelve-month target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $33.00. On average, they expect the company's share price to reach $21.44 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price.
View analysts price targets for ACAD
or view top-rated stocks among Wall Street analysts.

How have ACAD shares performed in 2023?

ACADIA Pharmaceuticals' stock was trading at $15.92 at the beginning of 2023. Since then, ACAD stock has increased by 18.2% and is now trading at $18.82.
View the best growth stocks for 2023 here
.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 8,500,000 shares, an increase of 5.7% from the February 28th total of 8,040,000 shares. Based on an average trading volume of 1,530,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 5.3% of the company's shares are short sold.
View ACADIA Pharmaceuticals' Short Interest
.

When is ACADIA Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ACAD earnings forecast
.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. The biopharmaceutical company earned $136.49 million during the quarter, compared to the consensus estimate of $135.18 million. ACADIA Pharmaceuticals had a negative net margin of 41.76% and a negative trailing twelve-month return on equity of 50.65%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.27) earnings per share.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $569.16 million.

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.64%), First Trust Advisors LP (1.78%), Morgan Stanley (1.70%), Geode Capital Management LLC (1.42%), JPMorgan Chase & Co. (1.29%) and Norges Bank (1.21%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends
.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $18.82.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.05 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

The company employs 514 workers across the globe.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872.

This page (NASDAQ:ACAD) was last updated on 4/1/2023 by MarketBeat.com Staff